Drug Profile
Research programme: antitussives - UCB
Alternative Names: Antitussives research programme - UCB; CP1Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator UCB
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cough
Most Recent Events
- 26 May 2005 Discontinued - Preclinical for Cough (Inhalation)
- 05 Nov 2002 UCB has acquired Cardiome Pharma's preclinical anti-tussive programme
- 05 Nov 2002 Preclinical trials in Cough (Inhalation)